Market Cap 3.54M
Revenue (ttm) 5.07M
Net Income (ttm) -10.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.79%
Debt to Equity Ratio 0.00
Volume 3,603,600
Avg Vol 2,547,218
Day's Range N/A - N/A
Shares Out 9.28M
Stochastic %K 12%
Beta 0.87
Analysts Strong Buy
Price Target $16.45

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4196
Address:
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States
DILF32
DILF32 May. 13 at 12:17 PM
$ENSC did the ctb really go from 100% to 440% overnight??
1 · Reply
Annet_why_net
Annet_why_net May. 13 at 12:03 PM
$ENSC II Why M&A is Nearly Impossible Toxic Overhang: Potential buyers must either buy out warrants at premium cash values or accept immediate equity dilution by hedge funds post-acquisition. The Most Likely Outcome For Institutional Investors Creditors short the underlying stock and use the S-3 registration to dump shares, extracting arbitrage profits while wiping out retail equity. For the Company The strategic alternatives review will likely result in a fire sale of intellectual property (MPAR/TAAP platforms) or a Chapter 11 bankruptcy restructuring, rendering common stock worthless.
0 · Reply
Annet_why_net
Annet_why_net May. 13 at 12:03 PM
$ENSC I The S-3 and Warrant Structure 1. Hyper-Dilution Over Restructuring New shares and warrants fund operational cash burn (working capital) rather than retiring legacy debt. 2. Conversion Death Spiral The $2M raise issued Series B preferred shares (initially convertible at $0.55) alongside 8.7 million warrants. With the stock crashing to $0.2761, strict down-round protectionforces the conversion price lower, creating massive, unchecked share dilution. 3. Capital Lock-Up Terms explicitly prohibit alternative variable-rate financing while Series B shares remain outstanding, leaving management's hands tied.
0 · Reply
Jbjb90
Jbjb90 May. 13 at 12:02 PM
$ENSC surely we have to be getting close to the bottom here, this was announced almost a month ago, I expect some kind of update before we hit below .20 or have to R/S 🤦‍♂️
0 · Reply
paolo73
paolo73 May. 13 at 11:48 AM
$ENSC they are incompetent scammers, never seen a company run by idiots like these incredible....idiots and dishonest
0 · Reply
ourscooby
ourscooby May. 13 at 11:27 AM
0 · Reply
StonkinDonuts
StonkinDonuts May. 13 at 11:23 AM
$ENSC why are we going down? It’s all good
0 · Reply
cherry_faced
cherry_faced May. 13 at 10:37 AM
$ENSC Below 0,3. No need to wait until August, soon for R/S.
0 · Reply
brokenowbaby
brokenowbaby May. 13 at 5:41 AM
$ENSC I’ll do more research thanks for the info. This seems like an under appreciated company .
0 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 4:48 AM
$ENSC vow 440 percent borrow rate. Bigggg Short Sqeeze
0 · Reply
Latest News on ENSC
Ensysce Biosciences announces publication on MPAR technology

2026-03-03T13:32:48.000Z - 2 months ago

Ensysce Biosciences announces publication on MPAR technology


Ensysce Biosciences initiates review of strategic alternatives

2026-02-25T13:17:50.000Z - 2 months ago

Ensysce Biosciences initiates review of strategic alternatives


Ensysce Biosciences expands global opioid patent portfolio

2026-01-21T13:15:40.000Z - 3 months ago

Ensysce Biosciences expands global opioid patent portfolio


Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 21, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio


Ensysce Biosciences receives EU patent for ADHD therapy

2026-01-08T13:52:10.000Z - 4 months ago

Ensysce Biosciences receives EU patent for ADHD therapy


Ensysce Biosciences Transcript: AGM 2025

Jan 7, 2026, 12:00 PM EST - 4 months ago

Ensysce Biosciences Transcript: AGM 2025


Ensysce Biosciences Issues Annual Shareholder Letter

Jan 5, 2026, 8:00 AM EST - 4 months ago

Ensysce Biosciences Issues Annual Shareholder Letter


Ensysce Biosciences secures $4M financing

2025-11-17T13:30:26.000Z - 6 months ago

Ensysce Biosciences secures $4M financing


Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:15 PM EST - 6 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results


Ensysce Biosciences initiates Phase 3 study of PF614

2025-07-16T12:16:08.000Z - 10 months ago

Ensysce Biosciences initiates Phase 3 study of PF614


Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq


Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split


DILF32
DILF32 May. 13 at 12:17 PM
$ENSC did the ctb really go from 100% to 440% overnight??
1 · Reply
Annet_why_net
Annet_why_net May. 13 at 12:03 PM
$ENSC II Why M&A is Nearly Impossible Toxic Overhang: Potential buyers must either buy out warrants at premium cash values or accept immediate equity dilution by hedge funds post-acquisition. The Most Likely Outcome For Institutional Investors Creditors short the underlying stock and use the S-3 registration to dump shares, extracting arbitrage profits while wiping out retail equity. For the Company The strategic alternatives review will likely result in a fire sale of intellectual property (MPAR/TAAP platforms) or a Chapter 11 bankruptcy restructuring, rendering common stock worthless.
0 · Reply
Annet_why_net
Annet_why_net May. 13 at 12:03 PM
$ENSC I The S-3 and Warrant Structure 1. Hyper-Dilution Over Restructuring New shares and warrants fund operational cash burn (working capital) rather than retiring legacy debt. 2. Conversion Death Spiral The $2M raise issued Series B preferred shares (initially convertible at $0.55) alongside 8.7 million warrants. With the stock crashing to $0.2761, strict down-round protectionforces the conversion price lower, creating massive, unchecked share dilution. 3. Capital Lock-Up Terms explicitly prohibit alternative variable-rate financing while Series B shares remain outstanding, leaving management's hands tied.
0 · Reply
Jbjb90
Jbjb90 May. 13 at 12:02 PM
$ENSC surely we have to be getting close to the bottom here, this was announced almost a month ago, I expect some kind of update before we hit below .20 or have to R/S 🤦‍♂️
0 · Reply
paolo73
paolo73 May. 13 at 11:48 AM
$ENSC they are incompetent scammers, never seen a company run by idiots like these incredible....idiots and dishonest
0 · Reply
ourscooby
ourscooby May. 13 at 11:27 AM
0 · Reply
StonkinDonuts
StonkinDonuts May. 13 at 11:23 AM
$ENSC why are we going down? It’s all good
0 · Reply
cherry_faced
cherry_faced May. 13 at 10:37 AM
$ENSC Below 0,3. No need to wait until August, soon for R/S.
0 · Reply
brokenowbaby
brokenowbaby May. 13 at 5:41 AM
$ENSC I’ll do more research thanks for the info. This seems like an under appreciated company .
0 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 4:48 AM
$ENSC vow 440 percent borrow rate. Bigggg Short Sqeeze
0 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 4:47 AM
$ENSC if tomorrow same price not rocket. 🚀. I will add more.
0 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 4:44 AM
$ENSC Ensc got patent in Usa. South America. Europe and Taiwan. Looks like some big international company interested to buy or merger. After interim results. Drug overdoses medication every country need. Specially if FDA approved. Something Big is brewing. May be lifetime opportunity soon. DYOR. This is opinion.
0 · Reply
StockDreamin
StockDreamin May. 13 at 4:23 AM
1 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 3:15 AM
$ENSC usually after issue millions of share yesterday and today there should be plenty share for shorts. 🩳 but. Zero available
0 · Reply
Sunnybhargava
Sunnybhargava May. 13 at 3:14 AM
$ENSC zero share available for shorts. 111%borrow rate. 🔥perfect short squeeze situation
0 · Reply
Jbjb90
Jbjb90 May. 12 at 11:12 PM
0 · Reply
cherry_faced
cherry_faced May. 12 at 9:27 PM
$ENSC For now, a depth charge instead of a missile. I hope you're right.
0 · Reply
BULLISH1975
BULLISH1975 May. 12 at 9:23 PM
$ENSC I will feel better once mgt have their free incentive shares because Then we will rocket in my opinion!!!! dyor
1 · Reply
Sunnybhargava
Sunnybhargava May. 12 at 8:34 PM
$ENSC someone buying big Millions for coming squeeze
1 · Reply
TheBullishOne007
TheBullishOne007 May. 12 at 8:07 PM
$ENSC Looks like Lynn played you again. 😬
0 · Reply
StockDreamin
StockDreamin May. 12 at 7:56 PM
$ENSC crapola!...shit market days dont help either!
1 · Reply
mrsparex
mrsparex May. 12 at 7:45 PM
$ENSC 🧐 New names on the board ...enticing holders to sell 🤔
0 · Reply